Although mTOR inhibitors, such as everolimus, have shown a beneficial effect in BHD patients (55), more clinical studies are needed to evaluate its efficacy of it in BHD-associated renal tumors. This evidence concerns the gene MTOR and Birt-Hogg-Dube syndrome.